THE EFFECT OF NECITUMUMAB IN COMBINATION WITH GEMCITABINE-CISPLATIN ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TOLERABILITY- SQUIRE TRIAL PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-EXPRESSING SQUAMOUS NSCLC TUMOURS
Author(s)
Reck M1, Socinski M2, Luft A3, Szczesna A4, Dediu M5, Ramlau R6, Losonczy G7, Molinier O8, Schumann C9, Brown J10, Soldatenkova V11, Chouaki N12, Thatcher N13
1Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany, 2UPMC Cancer Pavilion, Pittsburgh, PA, USA, 3Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation, 4Mazowieckie Centrum Leczenia Chorób Pluc, Otwock, Poland, 5Institute of Oncology "Alexandru Trestioreanu“, Bucharest, Romania, 6Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland, 7Semmelweis University Department of Pulmonology, Budapest, Hungary, 8Centre Hospitalier Le Mans, Le Mans, France, 9Clinic for Pulmonology, Thoracic Oncology, Sleep- and Respiratory Critical Care, Hospitals of Kempten-Oberallgaeu, Immenstadt im Allgäu, Germany, 10Eli Lilly and Company Limited, Windlesham, UK, 11Eli Lilly and Company, Bad Homburg, Germany, 12Eli Lilly and Company, Paris, France, 13The Christie Hospital, Manchester, UK
Conference/Value in Health Info
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCN221
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now